Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Lee Jackson | Jul 9, 2014 at 8:40 AM EDT

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit…

Jon C. Ogg | Jun 19, 2014 at 2:05 PM EDT

Will Celgene Trigger Other Biotech Stock Splits?

Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would…

Jon C. Ogg | Jun 19, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Amazon, Celgene, Cisco, FedEx, Starbucks and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, June 19, 2014. They include Amazon.com, Celgene,…

Jon C. Ogg | Jun 11, 2014 at 6:50 AM EDT

Short Sellers Remain Vigilant Against Top Biotech Stocks

ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger…

Trey Thoelcke | Jun 9, 2014 at 9:25 AM EDT

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally…

Jon C. Ogg | May 29, 2014 at 7:55 AM EDT

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 29, 2014. They include AngloGold Ashanti,…

Trey Thoelcke | May 22, 2014 at 8:40 AM EDT

Three Companies That Want to Cure Pancreatic Cancer

A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs…

Jon C. Ogg | May 8, 2014 at 8:35 AM EDT

RBC Doctor Panel Picks in Drugs and Biotech

In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six…

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Jon C. Ogg | Apr 22, 2014 at 12:00 PM EDT

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off…

Trey Thoelcke | Apr 10, 2014 at 8:00 AM EDT

Who Bucked the Short Interest Trend in Biotech Stocks?

Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back…

Trey Thoelcke | Apr 7, 2014 at 8:25 AM EDT

Credit Suisse Says Grit Your Teeth and Buy Biotech

In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016…

Jon C. Ogg | Apr 4, 2014 at 8:20 AM EDT

Stifel Says Strong Earnings Will Reignite Biotech Rally

ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering…

Jon C. Ogg | Apr 2, 2014 at 3:37 PM EDT

Biotech Giants Now Priced Like Old World Drug Stocks

Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position…

1 … 19 20 21 22 23 … 29

Celgene : CELG

All CELG Articles

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Will Celgene Trigger Other Biotech Stock Splits?

Top Analyst Upgrades and Downgrades: Amazon, Celgene, Cisco, FedEx, Starbucks and More

Short Sellers Remain Vigilant Against Top Biotech Stocks

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

Three Companies That Want to Cure Pancreatic Cancer

RBC Doctor Panel Picks in Drugs and Biotech

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

Who Bucked the Short Interest Trend in Biotech Stocks?

Credit Suisse Says Grit Your Teeth and Buy Biotech

Stifel Says Strong Earnings Will Reignite Biotech Rally

Biotech Giants Now Priced Like Old World Drug Stocks

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Will Celgene Trigger Other Biotech Stock Splits?

Top Analyst Upgrades and Downgrades: Amazon, Celgene, Cisco, FedEx, Starbucks and More

Short Sellers Remain Vigilant Against Top Biotech Stocks

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

Three Companies That Want to Cure Pancreatic Cancer

RBC Doctor Panel Picks in Drugs and Biotech

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

Who Bucked the Short Interest Trend in Biotech Stocks?

Credit Suisse Says Grit Your Teeth and Buy Biotech

Stifel Says Strong Earnings Will Reignite Biotech Rally

Biotech Giants Now Priced Like Old World Drug Stocks

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%